28187734|t|The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia.
28187734|a|BACKGROUND: Histone deacetylase inhibitor (HDACi), sodium butyrate (SB), has been shown to be neuroprotective in adult brain injury models. Potential explanation for the inhibitor action involves among others reduced inflammation. We therefore anticipated that SB will provide a suitable option for brain injury in immature animals. The aim of our study was to test the hypothesis that one of the mechanisms of protection afforded by SB after neonatal hypoxia-ischemia is associated with anti-inflammatory action. We examined the effect of SB on the production of inflammatory factors including analysis of the microglial and astrocytic cell response. We also examined the effect of SB on molecular mediators that are crucial for inducing cerebral damage after ischemia (transcription factors, HSP70, as well as pro- and anti-apoptotic proteins). METHODS: Seven-day-old rat pups were subjected to unilateral carotid artery ligation followed by 60 min of hypoxia (7.6% O2). SB (300 mg/kg) was administered in a 5-day regime with the first injection given immediately after hypoxic exposure. The damage of the ipsilateral hemisphere was evaluated by hematoxylin-eosin staining (HE) 6 days after the insult. Samples were collected at 24 and 48 h and 6 days. Effects of SB on hypoxia-ischemia (HI)-induced inflammation (cytokines and chemokine) were assessed by Luminex assay and immunohistochemistry. Expression of molecular mediators (NFkappaB, p53, HSP70, COX-2, pro- and anti-apoptotic factors Bax, Bcl-2, caspase-3) were assayed by Western blot analysis. RESULTS: SB treatment-reduced brain damage, as assessed by HE staining, suppressed the production of inflammatory markers-IL-1beta, chemokine CXCL10, and blocked ischemia-elicited upregulation of COX-2 in the damaged ipsilateral hemisphere. Furthermore, administration of SB promoted the conversion of microglia phenotype from inflammatory M1 to anti-inflammatory M2. None of the investigated molecular mediators that are known to be affected by HDACis in adults were modified after SB administration. CONCLUSIONS: Administration of SB is neuroprotective in neonatal hypoxia-ischemia injury. This neuroprotective activity prevented the delayed rise in chemokine CXCL10, IL-1beta, and COX-2 in the ipsilateral hemisphere. SB appears to exert a beneficial effect via suppression of HI-induced cerebral inflammation.
28187734	71	86	sodium butyrate	Chemical	MESH:D020148
28187734	103	111	hypoxia-	Disease	MESH:D000860
28187734	111	119	ischemia	Disease	MESH:D007511
28187734	172	187	sodium butyrate	Chemical	MESH:D020148
28187734	189	191	SB	Chemical	MESH:D020148
28187734	240	252	brain injury	Disease	MESH:D001930
28187734	338	350	inflammation	Disease	MESH:D007249
28187734	382	384	SB	Chemical	MESH:D020148
28187734	420	432	brain injury	Disease	MESH:D001930
28187734	555	557	SB	Chemical	MESH:D020148
28187734	573	580	hypoxia	Disease	MESH:D000860
28187734	581	589	ischemia	Disease	MESH:D007511
28187734	614	626	inflammatory	Disease	MESH:D007249
28187734	661	663	SB	Chemical	MESH:D020148
28187734	685	697	inflammatory	Disease	MESH:D007249
28187734	804	806	SB	Chemical	MESH:D020148
28187734	860	875	cerebral damage	Disease	MESH:D002539
28187734	882	890	ischemia	Disease	MESH:D007511
28187734	915	920	HSP70	Gene	108348108
28187734	991	994	rat	Species	10116
28187734	1075	1082	hypoxia	Disease	MESH:D000860
28187734	1089	1091	O2	Chemical	-
28187734	1094	1096	SB	Chemical	MESH:D020148
28187734	1193	1200	hypoxic	Disease	MESH:D002534
28187734	1269	1280	hematoxylin	Chemical	MESH:D006416
28187734	1387	1389	SB	Chemical	MESH:D020148
28187734	1393	1400	hypoxia	Disease	MESH:D000860
28187734	1401	1409	ischemia	Disease	MESH:D007511
28187734	1411	1413	HI	Disease	MESH:D020925
28187734	1423	1435	inflammation	Disease	MESH:D007249
28187734	1564	1567	p53	Gene	301300
28187734	1569	1574	HSP70	Gene	108348108
28187734	1576	1581	COX-2	Gene	26198
28187734	1615	1618	Bax	Gene	24887
28187734	1620	1625	Bcl-2	Gene	24224
28187734	1627	1636	caspase-3	Gene	25402
28187734	1686	1688	SB	Chemical	MESH:D020148
28187734	1707	1719	brain damage	Disease	MESH:D001925
28187734	1778	1790	inflammatory	Disease	MESH:D007249
28187734	1799	1807	IL-1beta	Gene	24494
28187734	1819	1825	CXCL10	Gene	245920
28187734	1839	1847	ischemia	Disease	MESH:D007511
28187734	1873	1878	COX-2	Gene	26198
28187734	1949	1951	SB	Chemical	MESH:D020148
28187734	1979	1988	microglia	Disease	
28187734	2004	2019	inflammatory M1	Disease	MESH:D015470
28187734	2028	2040	inflammatory	Disease	MESH:D007249
28187734	2123	2129	HDACis	Chemical	-
28187734	2160	2162	SB	Chemical	MESH:D020148
28187734	2210	2212	SB	Chemical	MESH:D020148
28187734	2244	2252	hypoxia-	Disease	MESH:D000860
28187734	2252	2267	ischemia injury	Disease	MESH:D007511
28187734	2339	2345	CXCL10	Gene	245920
28187734	2347	2355	IL-1beta	Gene	24494
28187734	2361	2366	COX-2	Gene	26198
28187734	2398	2400	SB	Chemical	MESH:D020148
28187734	2457	2459	HI	Disease	MESH:D020925
28187734	2468	2489	cerebral inflammation	Disease	MESH:D007249
28187734	Negative_Correlation	MESH:D020148	25402
28187734	Negative_Correlation	MESH:D020148	MESH:D007249
28187734	Negative_Correlation	MESH:D020148	MESH:D002534
28187734	Negative_Correlation	MESH:D020148	MESH:D000860
28187734	Negative_Correlation	MESH:D020148	26198
28187734	Positive_Correlation	MESH:D007511	26198
28187734	Association	MESH:D007249	245920
28187734	Negative_Correlation	MESH:D020148	MESH:D007511
28187734	Positive_Correlation	MESH:D020148	MESH:D015470
28187734	Negative_Correlation	MESH:D020148	MESH:D001930
28187734	Association	MESH:D007249	24494
28187734	Negative_Correlation	MESH:D020148	245920
28187734	Negative_Correlation	MESH:D020148	MESH:D020925
28187734	Negative_Correlation	MESH:D020148	MESH:D001925
28187734	Negative_Correlation	MESH:D020148	24494

